Philips and the University of Urbino in Italy are teaming up to develop magnetic nanoparticles that can translocate themselves inside red blood cells, and as such would act as a long lasting and, hopefully, non-harmful contrast agent. The researchers hope that such a contrast agent will be able to evade the immediate hepatic clearance, until after RBCs complete their life cycle.
The patented contrast agent techniques being developed by the University of Urbino are based on magnetic nanoparticles that are captured inside the patient’s own red blood cells, where they remain protected from the body’s excretion mechanisms for much longer periods. This could be as long as 120 days (the typical lifetime of healthy red blood cells). A key feature of the University of Urbino’s technology is that it could allow the preparation of relatively large volumes of contrast-agent loaded blood. Philips Research will take samples of this contrast-agent loaded blood and test its effectiveness in Philips scanners, using their in-depth knowledge of the physics involved to optimize the scan parameters.
The collaboration between Philips Research and the University of Urbino will last for approximately two and a half years, with expected initial applications in the treatment of cardiovascular disease – one of the biggest killers in the western world.
One way of treating heart rhythm disorders is a minimally invasive procedure known as radio-frequency ablation. During this procedure, a catheter is inserted into the patient’s heart and the tissue responsible for propagating abnormal electrical signals through the heart muscle is destroyed using heat from a radio-frequency field generated at the tip of the catheter. This is a complex procedure and may take hours to complete. Medical imaging technologies are used to direct these procedures. The images provide the maps that allow the interventional cardiologist to guide these instruments through the body to the relevant areas.
Encapsulated magnetic nanoparticles injected into a patient’s bloodstream could be used to highlight the volume of blood in the different heart chambers during such procedures. Injected as free particles, however, they would not remain in the bloodstream long enough for such operations to be successfully completed, because they would be too quickly excreted from the blood via the patient’s liver.
Press releases: Development of long retention-time contrast agents; Philips strikes healthcare research alliance with Italian University of Urbino for development of long retention-time contrast agents…
